Role of endoplasmic reticulum stress in apoptosis induced by HK2 inhibitor and its potential as a new drug combination strategy.


Journal

Cell stress & chaperones
ISSN: 1466-1268
Titre abrégé: Cell Stress Chaperones
Pays: Netherlands
ID NLM: 9610925

Informations de publication

Date de publication:
05 2022
Historique:
received: 20 02 2022
accepted: 22 03 2022
revised: 08 03 2022
pubmed: 1 4 2022
medline: 18 5 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Compared with normal cells, tumor cells mainly obtain energy through aerobic glycolysis. Hexokinase 2 (HK2) plays a key role in the regulation of tumor cell aerobic glycolysis, and targeting HK2 has become a new strategy for cancer treatment. However, little is known about the role of HK2 in colon cancer and the regulation of its targeted inhibitors. In this study, we found that the expression of HK2 in colorectal cancer tissues was significantly higher than that in adjacent tissues, and the expression level of HK2 in metastatic colorectal cancer was further increased. Meanwhile, the expression level of HK2 was closely related to clinical TNM stage and outcome of colorectal cancer patients. We provide here evidence that HK2 inhibitor 3-Bromopyruvate acid (3-BP) can significantly inhibit the survival and proliferation of colon cancer cells, and induce apoptosis through mitochondrial apoptosis signaling pathway. In addition, we found that 3-BP can also induce endoplasmic reticulum stress in colon cancer cells, the mechanism may be through the increase of intracellular calcium concentration. In vitro and in vivo experiments showed that inhibition of endoplasmic reticulum stress could further increase the proliferation inhibition and apoptosis induced by 3-BP. Collectively, our results show that HK2 is highly expressed in colorectal cancer. 3-BP, an inhibitor of HK2, can induce apoptosis and endoplasmic reticulum stress in colon cancer cells. Endoplasmic reticulum stress plays a protective role in cell death induced by 3-BP. This result suggested that targeting HK2 and endoplasmic reticulum stress may be a valuable strategy in targeted and combination therapy of colon cancer.

Identifiants

pubmed: 35355227
doi: 10.1007/s12192-022-01267-z
pii: 10.1007/s12192-022-01267-z
pmc: PMC9106785
doi:

Substances chimiques

Drug Combinations 0
Hexokinase EC 2.7.1.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-283

Informations de copyright

© 2022. The Author(s) under exclusive licence to [Cell Stress Society International.

Références

Biomed Res Int. 2015;2015:352794
pubmed: 25821797
Cell Death Dis. 2019 Jun 26;10(7):504
pubmed: 31243264
Mol Cancer. 2017 May 12;16(1):91
pubmed: 28499449
Gastroenterology. 2020 Jan;158(2):368-388
pubmed: 31563626
Pharmacol Rep. 2019 Dec;71(6):1184-1189
pubmed: 31669882
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Front Genet. 2021 Feb 24;12:635863
pubmed: 33719345
Biochemistry (Mosc). 2019 Oct;84(10):1117-1128
pubmed: 31694508
Theranostics. 2017 Jun 11;7(8):2339-2349
pubmed: 28740556
Wiley Interdiscip Rev Syst Biol Med. 2018 Mar;10(2):
pubmed: 28990735
Oncol Rep. 2018 Nov;40(5):2435-2444
pubmed: 30132536
Oncogene. 2018 Nov;37(45):5913-5925
pubmed: 29980790
Cancer Lett. 2018 Sep 1;431:105-114
pubmed: 29859300
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
Front Oncol. 2020 Jan 24;10:5
pubmed: 32038983
Cancers (Basel). 2019 Mar 08;11(3):
pubmed: 30857233
Trends Cancer. 2016 May;2(5):252-262
pubmed: 28741511
Cancers (Basel). 2021 Aug 19;13(16):
pubmed: 34439330
Crit Rev Biochem Mol Biol. 2018 Dec;53(6):667-682
pubmed: 30668176
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Front Med (Lausanne). 2020 Jul 30;7:351
pubmed: 32850882
Mol Cancer Res. 2018 Jul;16(7):1073-1076
pubmed: 29592897
Yeast. 2019 Apr;36(4):211-221
pubmed: 30462852
Cell Death Dis. 2019 Jan 10;10(1):30
pubmed: 30631039
Biochem Pharmacol. 2021 Oct;192:114737
pubmed: 34411568
Annu Rev Immunol. 2015;33:107-38
pubmed: 25493331
Biochim Biophys Acta. 2014 Oct;1843(10):2143-9
pubmed: 24440276
Int J Biol Sci. 2019 Jul 21;15(9):1905-1920
pubmed: 31523192
Cell. 2017 Feb 9;168(4):692-706
pubmed: 28187289
Cell Biol Int. 2013 Dec;37(12):1285-90
pubmed: 23881849
Med Sci (Basel). 2019 Jul 30;7(8):
pubmed: 31366129
Curr Med Chem. 2019;26(41):7285-7322
pubmed: 30543165
Annu Rev Pathol. 2015;10:173-94
pubmed: 25387057
Cell Mol Immunol. 2022 Jan;19(1):46-58
pubmed: 34239083
Int J Mol Sci. 2019 Sep 05;20(18):
pubmed: 31491919
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683

Auteurs

Jiateng Zhong (J)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China. jtzhong@xxmu.edu.cn.
Department of Gynecology, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, Henan, China. jtzhong@xxmu.edu.cn.

Shuya Lu (S)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Xiaoling Jia (X)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Qian Li (Q)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Lei Liu (L)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Pei Xie (P)

Department of Gynecology, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, Henan, China.

Guodong Wang (G)

Nursing School, Xinxiang Medical University, Xinxiang, China.

Manman Lu (M)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Wuji Gao (W)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.

Tiesuo Zhao (T)

Institute of Precision Medicine, Xinxiang Medical University, Xinxiang, Henan, China.
Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, Xinxiang Medical University, Xinxiang, Henan, China.

Qianqing Wang (Q)

Department of Gynecology, The Fourth Clinical College of Xinxiang Medical University, Xinxiang, Henan, China.

Wei Su (W)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China. hnswei@163.com.

Na Li (N)

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China. Lina@xxmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH